Back to research feed

Neurology

October 14, 2026 · via Europe PMC

Association Between Epilepsy and Young-Onset Dementia: Nationwide Data From France and Sweden.

Calonge Q, Geraudie A, Wei D, +7 more, Navarro V.

Journal ArticleAbstract only — full text under license

AI summary — for doctors, generated from the abstract only

Epilepsy was strongly associated with young-onset dementia in French and Swedish national data, with associations persisting after lagged analyses.

What was studied

Nested case-control analyses in France (11,360 cases, 113,600 controls) and Sweden (16,433 cases, 164,330 controls), plus a French retrospective cohort of adults aged 30-55 with incident epilepsy, examining epilepsy codes and antiseizure medication dispensation before young-onset dementia.

Key findings

  • In France 12.5% of cases versus 1.2% of controls had prior epilepsy codes (adjusted OR 3.76, 95% CI 3.42-4.14)
  • Ten-year cumulative dementia incidence was 2.20% with incident epilepsy (adjusted HR 6.02, 95% CI 4.98-7.26), 1.74% with prevalent epilepsy (HR 5.38) and 0.21% without epilepsy
  • Associations attenuated with longer lags but persisted beyond 5 years

Clinical relevance

Epilepsy in midlife, especially with multimorbidity, may warrant inclusion in dementia risk stratification and prevention efforts.

Who should care

Neurology

Limitations

Registry-based, so residual confounding and reverse causation (early dementia pathology causing seizures) remain possible despite lag analyses. The age definition of young-onset dementia is cut off in the abstract.

Epilepsy markedly raises young-onset dementia risk across two countries and designs, though causality is uncertain.

This is an AI-generated summary of the published abstract, not a clinical recommendation. It may not reflect the full text or subsequent updates — verify against the original source before acting on it.

Abstract

Background and objectives

Epilepsy is linked to late-onset dementia, but evidence for young-onset dementia (YOD; <65 years) is limited. We assessed the epilepsy-YOD association in France and Sweden and YOD risk after midlife epilepsy.

Methods

We conducted 3 nationwide analyses. A French nested case-control analysis included patients with incident YOD aged 40-64 years, diagnosed between January 1, 2016, and December 31, 2018. Index date was the first YOD-related health care event; controls were risk-set matched on age, sex, and region. A Swedish nested case-control replication included patients with YOD diagnosed between January 1, 1987, and December 31, 2016, with matched controls. In both studies, epilepsy-related diagnoses and antiseizure medication (ASM) dispensations were assessed up to 10 years before index date. Odds ratios (ORs) were estimated with conditional logistic regression. A French retrospective cohort included adults aged 30-55 years with incident epilepsy in 2008, matched to individuals with prevalent epilepsy before 2008 or no epilepsy. The cohort index was the first ASM reimbursement in the incident epilepsy group or the matched date for comparators. Follow-up ended at YOD, death, or 10 years. We estimated 10-year cumulative incidence and adjusted (comorbidities, deprivation) hazard ratios (HRs), treating death as a competing event. Sensitivity analyses included lagged entry up to 5 years.

Results

Case-control studies included 11,360 cases and 113,600 controls in France and 16,433 cases and 164,330 controls in Sweden. In France, 12.5% of YOD cases vs 1.2% of controls had previous epilepsy-related codes (adjusted OR 3.76, 95% CI 3.42-4.14), and 27.3% vs 10.3% had ASM dispensations (adjusted OR 1.44, 95% CI 1.36-1.52). The French cohort included 12,901 individuals with incident epilepsy, 64,083 with prevalent epilepsy, and 129,010 without epilepsy (mean age 44.0 years; 55.5% female participants). Ten-year cumulative YOD incidence was 2.20% (95% CI 1.94-2.48) with incident epilepsy (adjusted HR compared with individuals without epilepsy 6.02, 95% CI 4.98-7.26), 1.74% (1.64-1.85) with prevalent epilepsy (adjusted HR 5.38, 95% CI 4.64-6.25), and 0.21% (0.19-0.24) without epilepsy. Associations attenuated with longer lags but persisted beyond 5 years.

Discussion

Across 2 countries and complementary designs, epilepsy was strongly associated with YOD. Epilepsy conferred higher YOD risk in midlife, especially with multimorbidity, supporting epilepsy inclusion in YOD risk stratification and prevention.

DOI

10.1212/wnl.0000000000218700

PMID

42874008

Research metadata (titles, abstracts, authors, publication dates) is sourced from Europe PMC, which aggregates content from PubMed/MEDLINE, PubMed Central, and other providers under the U.S. National Library of Medicine (NLM/NCBI). NLM does not claim copyright on abstracts; the original journal publishers or authors may hold rights to the full articles. AI-generated summaries are derived only from the abstract, never the full text, and are always labeled as AI-generated.

Want more like this?

Browse more from the feed. A free account unlocks the full feed, saving and communities.

Back to the research feed

Create a free account · Sign in